Why Vertex Pharmaceuticals' Solid Q4 Results Weren't Good Enough
What's it going to take for Vertex Pharmaceuticals (NASDAQ: VRTX) to regain its mojo? Shares of the big biotech have a long way to go to recapture the highs set last year before Vertex reported disappointing clinical results for one of its alpha-1 antitrypsin deficiency (AATD) programs.
Unfortunately, any new mojo will probably be a no-go, at least for now. Vertex announced its fourth-quarter results after the market closed on Monday and there wasn't enough good news to excite investors. Here are the highlights from Vertex's Q4 update.
Image Source: Getty Images.
Source Fool.com
